Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score® test: ...

Exact Sciences' Oncotype DX Breast Recurrence Score test has now been used by more than 2,000,000 patients worldwide. The test is widely used to guide individualized breast cancer treatment and help ...

Onco-Innovations highlights three key aspects of the studies: the nanoparticle formulation of the PNKP compound's ability to target cancer site; the effectiveness of this formulation as a standalone ...

VANCOUVER, BC / ACCESS Newswire / September 12, 2025 / Onco-Innovations Limited (ONCO:CA)(Frankfurt:W1H)(WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")is pleased ...

VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce, further to its ...

Predicting tumor progression is one of the major challenges in oncology. Scientists at the University of Geneva (UNIGE) and ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...

An AI risk tool predicted death, bleeding, and ischaemic events after heart attack in patients with cancer, supporting ...

Renova Hospitals launches RIOS – Renova Institute of Onco Sciences to deliver coordinated, patient-centered multidisciplinary cancer care ...

The investigators reported the results of a prospective, randomized, phase 3 trial studying the best individual therapy for women who have node-negative, estrogen-receptor‒positive (ER-positive) ...

Dec. 09, 2025 6:00 PM ETOnco-Innovations Limited (ONCO:CA) "This fourth roundtable marks a pivotal moment as we are moving from vision to actionable roadmaps that will make precision oncology ...